PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 28, 2025JTCVS TechniquesOpen Access

Transvenous pacing leads implanted in epicardial position: A recipe for future epicardial pacing electrode?

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Finding an optimum epicardial pacing site in children needing lead replacement can be challenging.

Does the implantation of transvenous SelectSecure leads in the epicardial position provide acceptable pacing parameters in patients needing lead replacement?

Population

6 patients (5 children and 1 adult) receiving epicardial lead replacement

Comparison

Transvenous SelectSecure 3830 leads in the epicardial position

Design

Case series

Follow-up

23.4 (8-32) months

Key result

Implantation of transvenous SelectSecure leads in the epicardial position was feasible in patients with congenital heart disease and epicardial scarring, maintaining acceptable pacing parameters over a median 27-month follow-up.

Authors

SBSeraina BrütschCBChristian BalmerHDHitendu Dave

Discussion

Loading...

Member takes

Overview

Supports feasibility of epicardial SelectSecure leads in select pediatric reoperations; leaves open need for larger prospective studies.

Study Design

Type

Observational (n=6)

Multicenter

No

Structured PICO

Does the implantation of transvenous SelectSecure leads in the epicardial position provide acceptable pacing parameters in patients needing lead replacement?

P
Population
6 patients (5 children and 1 adult) with congenital heart disease and previous surgeries who received transvenous SelectSecure leads in the epicardial position, followed for a median of 27 months.
I
Intervention
Transvenous SelectSecure 3830 leads implanted in the epicardial position ('off-label')
O
Outcome
Periodic pacing threshold, sensing, and impedance measurementssurrogate

The off-label use of transvenous SelectSecure leads in the epicardial position is feasible and provides acceptable midterm pacing parameters for patients with multiple previous surgeries.

Limitations

  • Off-label use of the lead for epicardial implantation
  • Very small study population (6 patients)
  • Not a randomized case-controlled study
  • Short follow-up duration of 2.6 years limits conclusions on long-term outcomes
  • Small sample size
  • Need for longer follow-up

Cite This Study

Brütsch et al. (2025) conducted an observational in Congenital heart disease requiring permanent pacing (n=6). Transvenous SelectSecure 3830 leads in epicardial position was evaluated on Feasibility and lead performance (pacing threshold, sensing, and impedance). Implantation of transvenous SelectSecure leads in the epicardial position was feasible in patients with congenital heart disease and epicardial scarring, maintaining acceptable pacing parameters over a median 27-month follow-up.

synapsesocial.com/papers/6a4af206f6034ba310a870bfhttps://doi.org/10.1016/j.xjtc.2025.05.011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Permanent Epicardial and Transvenous Single- and Dual-Chamber Cardiac Pacing in Children1993 · 26 citations
  2. 2Novel direct approach for placement of permanent transvenous pacing leads after Fontan procedure2018 · 5 citations
  3. 3Risk Factors for Venous Obstruction in Children with Transvenous Pacing Leads1997 · 137 citations
  4. 4Twenty years experience with pediatric pacing: epicardial and transvenous stimulation2000 · 159 citations
  5. 5Feasibility of epicardial implantation of medtronic 3830 lead in a pediatric patient : case report2024 · 2 citations